New antifungal drug could shield liver transplant patients from deadly infections
NCT ID NCT06774144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new antifungal drug called rezafungin can prevent serious fungal infections in people who have had a liver transplant. About 385 adults at high risk for infection will receive the drug, and their outcomes will be compared to similar patients from the past two years. The goal is to see if rezafungin reduces infections and improves survival without harming the new liver.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Presbyterian
Pittsburgh, Pennsylvania, 15213, United States